Journal article
Persistence and efficacy of second generation CAR T Cell against the LeY Antigen in acute myeloid leukemia
DS Ritchie, PJ Neeson, A Khot, S Peinert, T Tai, K Tainton, K Chen, M Shin, DM Wall, D Hönemann, P Gambell, DA Westerman, J Haurat, JA Westwood, AM Scott, L Kravets, M Dickinson, JA Trapani, MJ Smyth, PK Darcy Show all
Molecular Therapy | Published : 2013
DOI: 10.1038/mt.2013.154
Abstract
In a phase I study of autologous chimeric antigen receptor (CAR) anti-LeY T-cell therapy of acute myeloid leukemia (AML), we examined the safety and postinfusion persistence of adoptively transferred T cells. Following fludarabine-containing preconditioning, four patients received up to 1.3 × 109 total T cells, of which 14-38% expressed the CAR. Grade 3 or 4 toxicity was not observed. One patient achieved a cytogenetic remission whereas another with active leukemia had a reduction in peripheral blood (PB) blasts and a third showed a protracted remission. Using an aliquot of In111-labeled CAR T cells, we demonstrated trafficking to the bone marrow (BM) in those patients with the greatest clin..
View full abstractGrants
Funding Acknowledgements
We acknowledge the research funding from the Leukemia Lymphoma Society (USA) Translational Research Programme and the National Health and Medical Research Council and the generous philanthropic support of Maree and Chris Morris. M.J.S. was supported by a NH&MRC Australia Fellowship. M. H. K. and P. K. D. were supported by NH&MRC Senior Research Fellowships. We also acknowledge the expert contribution of Stephen Lade in the completion of the immunohistochemistry studies.